Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03631667 · ClinicalTrials.gov registry record · Early Phase 1

Ultralow Dose PAH Binary Mixture Study

A Early Phase 1 study of Environmental Exposure, sponsored by Oregon State University.

Completed
Registry status
Early Phase 1
Development phase
8
Enrollment target
1
Study location

NCT03631667 is a Early Phase 1 study of Environmental Exposure that has completed, run by Oregon State University. The registered enrollment target is 8 participants, below the 290-participant average among 13 other Environmental Exposure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03631667, a Early Phase 1 study of Environmental Exposure, has completed, sponsored by Oregon State University.

COMPLETED
Registry status
Early Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.

Conditions Studied

Interventions

  • DRUG [14C]-benzo[a]pyrene
  • DRUG [14C]-benzo[a]pyrene plus phenanthrene

Study Locations (1)

Oregon

  • Oregon State University - Corvallis

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2018-10-01
Est. Completion 2024-02-01
Phase Early Phase 1

Sponsor

Oregon State University

33 total trials

What the Registry Record Tells You About NCT03631667

The ClinicalTrials.gov registry entry for NCT03631667 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 290-participant average among 13 other Environmental Exposure trials with a reported enrollment target (97% lower). The listed sponsor is Oregon State University, which has 33 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Environmental Exposure appearing as the primary indexed condition, and to 2 interventions - of which [14C]-benzo[a]pyrene is the first listed.

NCT03631667 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT03631667 about?

NCT03631667 is a clinical study titled "Ultralow Dose PAH Binary Mixture Study". Evaluation of the pharmacokinetics for \[14C\]-benzo\[a\]pyrene (\[14C\]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.

What is the current status of trial NCT03631667?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2018-10-01. Estimated completion is 2024-02-01.

What conditions does trial NCT03631667 study?

This clinical trial studies the following conditions: Environmental Exposure.

What interventions are being tested in trial NCT03631667?

The interventions under investigation include: [14C]-benzo[a]pyrene (DRUG), [14C]-benzo[a]pyrene plus phenanthrene (DRUG).

Who is sponsoring clinical trial NCT03631667?

This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03631667 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Environmental Exposure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.